Literature DB >> 9439378

Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration.

K T Oh1, H C Boldt, R P Danis.   

Abstract

PURPOSE: To describe a patient with iatrogenically induced central retinal vein occlusions secondary to serum hyperviscosity from intravenous immunoglobulin administration.
METHOD: Case report.
RESULTS: The patient developed bilateral central retinal vein occlusions in association with high-dose intravenous immunoglobulins. The central retinal vein occlusions resolved when the immunoglobulins were withheld and serum hyperviscosity decreased.
CONCLUSION: Administration of high-dose intravenous immunoglobulins can be associated with hyperviscosity syndrome manifested by central retinal vein occlusion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439378     DOI: 10.1016/s0002-9394(14)70844-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 2.  Intravenous immunoglobulin: adverse effects and safe administration.

Authors:  Hedi Orbach; Uriel Katz; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Bilateral neovascular glaucoma due to multicentric Castleman disease.

Authors:  Takayasu Omata; Teruhiko Hamanaka; Soichiro Ikushima; Masaru Oritsu
Journal:  Jpn J Ophthalmol       Date:  2008-03-28       Impact factor: 2.447

4.  Sequential bilateral central retinal vein occlusions in a cystic fibrosis patient with hyperhomocysteinemia and hypergamma-globulinemia.

Authors:  Rony Gelman; Emily A DiMango; William M Schiff
Journal:  Retin Cases Brief Rep       Date:  2013

5.  Treatment of pediatric optic neuritis.

Authors:  Gabrielle R Bonhomme; Ellen B Mitchell
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.972

6.  Treatment of acute optic neuritis and vision complaints in multiple sclerosis.

Authors:  Ruben Torres-Torres; Bernardo F Sanchez-Dalmau
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.972

Review 7.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.